A new study finds that the use of adjuvant systemic therapy for localized gastrointestinal stromal tumors (GISTs ) has significantly increased over time and that patients treated with the therapy have better survival than ...
Mar 2, 2015
0
3
Researchers at the University of California, San Diego School of Medicine have, for the first time, clearly defined the epidemiology of gastrointestinal stromal tumors (GIST), which occur primarily in the lining of the stomach ...
Oct 7, 2014
0
0
The Ohio State University, through the Ohio State Innovation Foundation, has signed an exclusive world-wide licensing agreement with MedVax Technologies, Inc., for the licensing of groundbreaking cancer peptide vaccine technologies.
Mar 18, 2014
0
0
University of Pittsburgh Cancer Institute (UPCI) scientists have shown that old drugs might be able to do new tricks.
Feb 13, 2014
0
0
An international research team led by University of Pittsburgh Cancer Institute (UPCI) scientists discovered that by preventing cancer cells from entering a state of cellular sleep, cancer drugs are more effective, and there ...
Aug 1, 2013
0
0
Interim results of an EORTC intergroup trial have confirmed that adjuvant imatinib impacts short-term freedom from relapse in patients with localized, surgically resected, high/ intermediate-risk GIST. In the high-risk subgroup, ...
May 29, 2013
0
0
A new preclinical technology enables researchers to quickly determine if a particular treatment is effective against gastrointestinal stromal tumors (GISTs), providing a boost to animal research and possibly patient care, ...
Apr 9, 2013
0
0
A new blood test revealed more of the gene mutations that sustain certain digestive-tract tumors than did a DNA analysis of a traditional tumor biopsy, Dana-Farber Cancer Institute investigators will report at a special symposium ...
Apr 7, 2013
0
0
The U.S. Food and Drug Administration on Monday expanded approval of a Bayer cancer pill to treat tumors of the intestinal tract that do not respond to other treatments.
Feb 25, 2013
0
0
An antibody that binds to a molecule on the surface of a rare but deadly tumor of the gastrointestinal tract inhibits the growth of the cancer cells in mice, according to researchers at the Stanford University School of Medicine.
Feb 4, 2013
0
1
